Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (744)	12/3/1999 12:38:00 AM
From: Lance Bredvold	Respond to of 10345

The following site was offered on the Immunomedics Yahoo board. I went, looked around a bit, and thought perhaps you guys would appreciate it. Guess I've mentioned that ELN has worked its way up to 4th largest in my portfolio now.: I looked up Elan and found 48 articles published by different scientists over the last 4 years. Ziconotide brought up other data. L. PubMed by: iron2_1999 12/1/1999 11:59 pm EST Msg: 5172 of 5214I made reference to PubMed in the previous post. It occurs to me that many of the non-scientist posters may not be aware of this powerful resource. One can search not only by subject but also by affiliation (company name) or author. A great way to check out whether a company is for real in peer-reviewed publications and what kind of science different companies are involved in. ncbi.nlm.nih.gov All this and it is free.

To: William Partmann who wrote (744)	12/4/1999 3:04:00 PM
From: Gary Korn	Read Replies (1) \| Respond to of 10345

12/3/99 Dow Jones News Serv. 02:17:00 Dow Jones News Service Copyright (c) 1999, Dow Jones & Company, Inc. Friday, December 3, 1999 Elan Pharmaceutical Releases Botulinum Toxin Phase 3 Results SO. SAN FRANCISCO, Calif. -(Dow Jones)- Elan Corp. PLC's (ELN) Elan Pharmaceuticals Inc. unit said two Phase 3 clinical trials found its Botulinum toxin Type B injectable solution may help some cervical dystonia patients. The two separate studies evaluated the drug's ability to decrease the pain, severity and disability of cervical dystonia, a movement disorder. In a press release, Elan Pharmaceuticals said it included the studies in a December 1998 product license application under review by the Food and Drug Administration. Side effects included dry mouth and difficulty swallowing and were generally mild to moderate. The Botulinum toxin Type B, which is injected directly into affected muscles, relaxes them by interrupting nerve transmissions. -Alan Paris; Dow Jones Newswires; 201-938-5400 ---- INDEX REFERENCES ----

To: William Partmann who wrote (744)	12/6/1999 12:17:00 AM
From: Gary Korn	Read Replies (2) \| Respond to of 10345

From Merrill's 12/2 research report on ELN: Investment Highlights: ú Elan?s Alzheimer?s disease R&D program continues to attract attention in the scientific community. An article today in the prestigious journal, Nature, highlights recent advances in the beta-secretase hypothesis, an enzyme involved with amyloid plaque formation, as a causal factor in Alzheimer?s disease. ú Beta-secretase agents are another aspect of Elan?s research effort, and is distinct from its vaccine candidate, AN-1792. We believe that Elan has identified several preclinical candidates, which may position it as a front-runner among companies, such as Pharmacia & Upjohn, SmithKline Beecham and Amgen, which are also active in the area. ú We expect AN-1792 to begin Phase I human trials shortly. The clinical program involves one dose in up to 30 patients having mild disease. The primary endpoint will be to establish safety. We expect a second Phase I trial, involving multiple doses, to be initiated in the U.K. during the first quarter. ú We continue to believe that overall fundamentals remain on track. We expect NDA filing for ziconotide before year-end and first quarter launches of Zonagren and Neurobloc. Frovatriptan should be launched in early2001. ú With financial issues no longer of great relevance, we expect the focus to be on the impending FDA approval, filings and launches of key products. Although Elan appears to be establishing itself as a world leader in Alzheimer?s disease research, it is not yet a factor in the company?s valuation. ú The stock?s P/E remains at a significant discount to projected EPS growth. Improved quality of earnings, now that R&D vehicles are being acquired, a strong new product launch schedule for 2000-2001, and rising scientific visibility, should fuel a higher P/E, more in line with projected earnings growth. Our $45 price objective is reaffirmed.